The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.
about
Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementationWarfarin pharmacogenetics: does more accurate dosing benefit patients?Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicityA gene-based association method for mapping traits using reference transcriptome dataSTRATEGIES FOR EQUITABLE PHARMACOGENOMIC-GUIDED WARFARIN DOSING AMONG EUROPEAN AND AFRICAN AMERICAN INDIVIDUALS IN A CLINICAL POPULATIONEthnicity-specific pharmacogenetics: the case of warfarin in African AmericansWarfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study.Genotype-based dosing algorithms for warfarin therapy: data review and recommendations.Warfarin pharmacogenetics.Pathway analysis of genome-wide data improves warfarin dose prediction.Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.Pharmacogenomics: application to the management of cardiovascular diseaseCardiovascular pharmacogenomicsNovel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans.Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans.Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALURace influences warfarin dose changes associated with genetic factors.CYP2C9 promoter variable number tandem repeat polymorphism regulates mRNA expression in human livers.Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.The future of warfarin pharmacogenetics in under-represented minority groups.Personalized medicine: is it a pharmacogenetic mirage?Role of cytochrome P450 genotype in the steps toward personalized drug therapy.Pharmacogenomics of warfarin in populations of African descent.Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans.The limits of genome-wide methods for pharmacogenomic testing.Role of pharmacogenomics in the management of traditional and novel oral anticoagulantsPharmacogenetics and cardiovascular disease--implications for personalized medicineGenome-wide approaches in pharmacogenomics: heritability estimation and pharmacoethnicity as primary challengesGenetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.A pharmacogenetics service experience for pharmacy students, residents, and fellows.Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism.Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.Cytochrome P450 pharmacogenetics in African populations.Priority pharmacogenetics for the African continent: focus on CYP450.Warfarin Pharmacogenomics in Diverse Populations.DNA sensors to assess the effect of VKORC1 and CYP2C9 gene polymorphisms on warfarin dose requirement in Chinese patients with atrial fibrillation.Effect of Tranexamic Acid on Hematologic Values and Blood Loss in Reverse Total Shoulder Arthroplasty.Warfarin dose requirements in a patient with the CYP2C9*14 allele
P2860
Q26823542-1244A752-B612-403D-8588-B668DDBAC4A0Q27011524-FCFAAF7B-6EE3-4E3D-AC10-FF710AE04DC0Q27027304-8C2DACED-5875-475C-A1A7-BC3CE6671EDDQ28083100-E2ADE9D5-995C-483C-8269-23D92EE8D0AEQ28608356-D9ACC7BF-A504-43C5-8F4A-6A8E96F650CCQ33557032-9CD5768E-1B42-43FC-A8AB-B0315BEDBEA4Q33591111-C3947DC4-C3B0-43C3-849B-D0F3E59E7097Q33770184-9BE78600-6D23-496B-9A09-2F50C1851FD4Q34065133-E2C0EB89-AD1A-46F4-827E-736AFB2CDB48Q34785072-FED8663D-B1C8-45F3-BBFA-E9CCB7C26E29Q34790566-BDD8A411-6BDB-4098-BF31-4BA23517AE11Q34791041-E1FD6B59-E6FD-499C-908D-FB1665065FFFQ35309161-81C10276-F71D-47D1-9E36-360DC5D0A9B6Q35447163-D1C68ED7-7765-4FA9-ABB0-7C647BA661C6Q35612111-C6D75E54-CC21-4849-AEE2-15C45B8AD6EEQ35681000-C362385B-9650-4214-B328-9883052C50B3Q35795982-D2B8D54B-E14A-4105-B9B8-38DFB4FADC5AQ35884265-7E3D8FCD-4EEA-42B1-BF10-51D658ED06DFQ35913092-0C12C62C-C61C-4BE3-B034-ECE3007E422AQ35991881-24BDE786-6CCE-40BA-825B-D639FE805301Q36094919-CBC9078B-011F-48D5-B84A-C052D0C04505Q36294461-243EECE4-8B4D-4C89-87BA-5845AFE33440Q36336007-037F1414-3564-4EAA-B99B-116F1626D128Q36441521-3D5A70D2-6DCD-489C-B1BC-A3E489AC2701Q36629209-A7B79D83-48E2-4F2A-A86C-C3B322C3C304Q36651620-4E2D72F4-2BFF-4F92-BE04-8218A529F0D3Q36848413-8765A4A5-2234-4C79-A180-6788CC90F678Q36848449-0C6574E2-CAD8-4A85-9705-3989D65DB50AQ36974672-96DAC4E3-8E17-41B4-9457-2E664B8F0D9BQ37010277-B54320DE-4988-4526-9171-937683B0ABA3Q37138272-126EC4DA-A1AB-4278-90B1-6C9EFA4E965EQ37251749-E2B46444-95C1-40F2-BCF2-1F026CCBE8A5Q37429282-7389DED3-9C46-430C-9FC5-9E11BA910A23Q38078754-08D56A26-F632-4344-9499-57E5590E06B8Q38099372-DF725247-AE6D-4618-914D-5C3289D8F2D1Q38188600-A11B4B8B-877E-4558-82D4-08431C38BF37Q38696567-F7C2EABF-F51C-4D2D-A00B-5105FD24BFE5Q39022910-DBBC77B0-34B3-40B4-9F35-6B378D5950A5Q41341203-BDA7DD49-5171-4AD6-A409-04124A7BA679Q42088252-7D8AA8DC-70B1-417B-B592-FA326711103B
P2860
The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
The missing association: seque ...... rin dose in African Americans.
@ast
The missing association: seque ...... rin dose in African Americans.
@en
type
label
The missing association: seque ...... rin dose in African Americans.
@ast
The missing association: seque ...... rin dose in African Americans.
@en
prefLabel
The missing association: seque ...... rin dose in African Americans.
@ast
The missing association: seque ...... rin dose in African Americans.
@en
P2093
P2860
P356
P1476
The missing association: seque ...... rin dose in African Americans.
@en
P2093
L H Cavallari
M A Perera
R A Kittles
S Poindexter
P2860
P304
P356
10.1038/CLPT.2010.322
P407
P577
2011-01-26T00:00:00Z